Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - pdr for soln for injection - 3.5 milligram - other antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - pdr for soln for injection - 3.5 milligram - other antineoplastic agents

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

janssen-cilag ltd - bortezomib - powder for solution for injection - 3.5mg

Israel - English - Ministry of Health

j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Israel - English - Ministry of Health

j-c health care ltd - bortezomib 1 mg - powder for solution for injection - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma. velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - bortezomib - injection, powder, for solution - 3.5mg - bortezomib 3.5mg

Malta - English - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - bortezomib - multiple myeloma - antineoplastic agents - bortezomib accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with haematopoietic stem cell transplantation.bortezomib accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Malta - English - Medicines Authority

teva b.v. swensweg 5, 2031 ga haarlem, netherlands - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents